JP2007532496A5 - - Google Patents

Download PDF

Info

Publication number
JP2007532496A5
JP2007532496A5 JP2007506660A JP2007506660A JP2007532496A5 JP 2007532496 A5 JP2007532496 A5 JP 2007532496A5 JP 2007506660 A JP2007506660 A JP 2007506660A JP 2007506660 A JP2007506660 A JP 2007506660A JP 2007532496 A5 JP2007532496 A5 JP 2007532496A5
Authority
JP
Japan
Prior art keywords
solid
reaction
esters
mmol
solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007506660A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007532496A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/DK2005/000244 external-priority patent/WO2005097107A2/en
Publication of JP2007532496A publication Critical patent/JP2007532496A/ja
Publication of JP2007532496A5 publication Critical patent/JP2007532496A5/ja
Pending legal-status Critical Current

Links

JP2007506660A 2004-04-08 2005-04-08 ジフェニルオキソ−インドール−2−オン化合物および癌の処置におけるそれらの使用 Pending JP2007532496A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DKPA200400576 2004-04-08
DKPA200400693 2004-05-01
DKPA200401153 2004-07-27
DKPA200401216 2004-08-11
PCT/DK2005/000244 WO2005097107A2 (en) 2004-04-08 2005-04-08 Diphenyl - indol-2-on compounds and their use in the treatment of cancer

Publications (2)

Publication Number Publication Date
JP2007532496A JP2007532496A (ja) 2007-11-15
JP2007532496A5 true JP2007532496A5 (https=) 2008-05-22

Family

ID=34965522

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007506660A Pending JP2007532496A (ja) 2004-04-08 2005-04-08 ジフェニルオキソ−インドール−2−オン化合物および癌の処置におけるそれらの使用

Country Status (15)

Country Link
US (1) US20070299102A1 (https=)
EP (1) EP1734951A2 (https=)
JP (1) JP2007532496A (https=)
KR (1) KR20060130781A (https=)
CN (1) CN1953747A (https=)
AU (1) AU2005230232A1 (https=)
BR (1) BRPI0509745A (https=)
CA (1) CA2562399A1 (https=)
CR (1) CR8673A (https=)
EA (1) EA013209B1 (https=)
EC (1) ECSP066913A (https=)
IL (1) IL178012A0 (https=)
NO (1) NO20065034L (https=)
NZ (1) NZ550222A (https=)
WO (1) WO2005097107A2 (https=)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4989976B2 (ja) 2004-02-13 2012-08-01 プレジデント アンド フェロウズ オブ ハーバード カレッジ 翻訳開始阻害剤としての3−3−二置換オキシインドール
AR053710A1 (es) * 2005-04-11 2007-05-16 Xenon Pharmaceuticals Inc Compuestos espiroheterociclicos y sus usos como agentes terapeuticos
AR056968A1 (es) * 2005-04-11 2007-11-07 Xenon Pharmaceuticals Inc Compuestos espiro-oxindol y composiciones farmacéuticas
AR053713A1 (es) * 2005-04-20 2007-05-16 Xenon Pharmaceuticals Inc Compuestos heterociclicos y sus usos como agentes terapeuticos
CA2626456C (en) 2005-10-18 2018-01-09 George Mason Intellectual Properties, Inc. Mtor pathway theranostic
US20110294842A9 (en) * 2006-10-12 2011-12-01 Xenon Pharmaceuticals Inc. Spiro (furo [3, 2-c] pyridine-3-3' -indol) -2' (1'h)-one derivatives and related compounds for the treatment of sodium-channel mediated diseases, such as pain
WO2008060789A2 (en) * 2006-10-12 2008-05-22 Xenon Pharmaceuticals Inc. Use of spiro-oxindole compounds as therapeutic agents
AU2007307635A1 (en) * 2006-10-12 2008-04-17 Xenon Pharmaceuticals Inc. Tricyclic spiro-oxindole derivatives and their uses as therapeutic agents
WO2008071387A1 (en) * 2006-12-11 2008-06-19 Topotarget A/S Prodrugs of diphenyl ox- indol- 2 -one compounds for the treatment of cancers
JP2010525024A (ja) * 2007-04-24 2010-07-22 トポターゲット・アクティーゼルスカブ 置換3−(4−ヒドロキシフェニル)−インドリン−2−オン化合物
NZ587719A (en) 2008-02-26 2012-04-27 Takeda Pharmaceutical Fused heterocyclic derivative and use thereof
US20100048913A1 (en) 2008-03-14 2010-02-25 Angela Brodie Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens;Synthesis In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
CA2719134C (en) 2008-03-21 2015-06-30 The University Of Chicago Treatment with opioid antagonists and mtor inhibitors
JO3032B1 (ar) 2008-10-17 2016-09-05 Xenon Pharmaceuticals Inc مركبات سبيرو – اوكسندول وإستعمالاتها كعوامل علاجية.
CA2741024A1 (en) * 2008-10-17 2010-04-22 Xenon Pharmaceuticals Inc. Spiro-oxindole compounds and their use as therapeutic agents
US8110578B2 (en) * 2008-10-27 2012-02-07 Signal Pharmaceuticals, Llc Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway
CN102686600A (zh) 2009-02-05 2012-09-19 托凯药业股份有限公司 甾体cyp17抑制剂/抗雄激素物质的新型药物前体
WO2010109008A1 (en) 2009-03-26 2010-09-30 Topotarget A/S Prodrugs of substituted 3-(4-hydroxyphenyl)-indolin-2-ones
AR077252A1 (es) 2009-06-29 2011-08-10 Xenon Pharmaceuticals Inc Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos
US20110086899A1 (en) * 2009-10-14 2011-04-14 Xenon Pharmaceuticals Inc. Pharmaceutical compositions for oral administration
KR20120099429A (ko) 2009-10-14 2012-09-10 제논 파마슈티칼스 인크. 스피로-옥스인돌 화합물의 합성 방법
AP2012006277A0 (en) * 2009-10-23 2012-06-30 Health Research Inc Method for treating androgen receptor positive cancers.
WO2011106729A2 (en) 2010-02-26 2011-09-01 Xenon Pharmaceuticals Inc. Pharmaceutical compositions of spiro-oxindole compound for topical administration and their use as therapeutic agents
CA2898732A1 (en) * 2013-01-18 2014-07-24 Mao CHENGJIAN Estrogen receptor inhibitors
RU2015137617A (ru) 2013-03-14 2017-04-18 Юниверсити Оф Мэриленд, Балтимор Офис Оф Текнолоджи Трансфер Агенты, подавляющие андрогенные рецепторы, и их применение
CN105636594A (zh) 2013-08-12 2016-06-01 托凯药业股份有限公司 使用雄激素靶向疗法用于治疗肿瘤性疾病的生物标记物
CA2935167C (en) 2014-01-16 2022-02-22 Musc Foundation For Research Development Targeted nanocarriers for the administration of immunosuppressive agents
WO2016127068A1 (en) 2015-02-05 2016-08-11 Teva Pharmaceuticals International Gmbh Methods of treating postherpetic neuralgia with a topical formulation of a spiro-oxindole compound
US20210220329A1 (en) * 2018-02-08 2021-07-22 The United State of America, as represented by the Secretary, Department of Health and Human Service A method of treating triple-negative breast cancer
JP2021529757A (ja) 2018-07-03 2021-11-04 ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ イリノイ 小胞体ストレス応答の活性剤
EP3912625A1 (en) * 2020-05-20 2021-11-24 Kaerus Bioscience Limited Novel maxi-k potassium channel openers for the treatment of fragile x associated disorders
CN114213396B (zh) * 2022-01-27 2023-03-24 深圳市乐土生物医药有限公司 一种吲哚-2-酮类化合物及其制备方法与用途
CN119019312B (zh) * 2024-10-24 2025-01-28 苏州宜联生物医药有限公司 一种吲哚-2-酮衍生物、其抗体药物偶联物及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2258505A1 (de) * 1971-12-02 1973-06-07 Ciba Geigy Ag Oxindoldiamine und verfahren zu ihrer herstellung
ES426436A1 (es) * 1974-05-18 1976-07-01 Andreu Sa Dr Procedimiento para la obtencion de derivados de la 3,3-bis (4-hidroxifenil)-2-indolinona.
JPS5590943A (en) * 1978-12-28 1980-07-10 Fuji Photo Film Co Ltd Photosensitive material and image forming method applicable thereto
DE3510730A1 (de) * 1985-03-08 1986-09-11 Möve-Werk GmbH & Co KG, 7410 Reutlingen Verfahren zur herstellung eines baumwollgewebes
EP1047411B1 (en) * 1997-11-20 2004-02-11 President And Fellows Of Harvard College Substituted diphenyl indanone, indane and indole compounds and analogues thereof useful for the treatment or prevention of diseases characterized by abnormal cell proliferation
US6800658B2 (en) * 1997-11-20 2004-10-05 Children's Medical Center Corporation Substituted diphenyl indanone, indane and indole compounds and analogues thereof useful for the treatment of prevention of diseases characterized by abnormal cell proliferation
US6391907B1 (en) * 1999-05-04 2002-05-21 American Home Products Corporation Indoline derivatives
WO2003078394A1 (en) * 2002-03-15 2003-09-25 Eli Lilly And Company Dihydroindol-2-one derivatives as steroid hormone nuclear receptor modulators
JP4989976B2 (ja) * 2004-02-13 2012-08-01 プレジデント アンド フェロウズ オブ ハーバード カレッジ 翻訳開始阻害剤としての3−3−二置換オキシインドール

Similar Documents

Publication Publication Date Title
JP2007532496A5 (https=)
JP2019510128A (ja) スガマデクスの調製のための改善されたプロセス
JP2011503053A (ja) 2‐ヒドロキシ‐5‐フェニルアルキルアミノ安息香酸誘導体及びその塩の製造方法
JP2002513003A5 (https=)
WO2019137358A1 (zh) 一种parp抑制剂及其中间体的制备方法
CN1108029A (zh) 克拉维酸的二胺盐
WO2010083722A1 (zh) 一锅煮方法合成corey内酯的工艺
JP2008201739A (ja) エダラボンの製造方法
JP2010043053A (ja) 高純度のレバミピドの製造方法
JP4433365B2 (ja) 4−(2−メチル−1−イミダゾリル)−2,2−ジフェニルブタンアミドの製造方法
CN111909067A (zh) 一种d-青霉胺的有机全合成方法
US6861525B2 (en) Process for the preparation imidazo[1,2-A]pyridine-3-acetamides
JPH02229196A (ja) セファロスポリン誘導体およびそれらの製法
DE60108112D1 (de) Verfahren zur herstellung von carbostyril-derivaten
CN112812101A (zh) 一种阿伐那非杂质的制备方法
JP5087059B2 (ja) 4−(2−メチル−1−イミダゾリル)−2,2−ジフェニルブタンアミドの製造方法
CN111978264B (zh) 一种地拉罗司的工业化生产方法
AU604583B2 (en) Process for the preparation of a benzoic acid ester
JP3899626B2 (ja) 2−メルカプトチアゾ−ルの製法
JP4675234B2 (ja) 光学活性なキノロンカルボン酸誘導体の製造中間体およびその製造法
CN108484495B (zh) 一种3-溴-7-羟基喹啉的合成方法
JP4500160B2 (ja) アミドフェノールの製造法
CN107674023A (zh) 一种瑞巴派特的合成方法
EP0435995A1 (en) New quinoline derivatives and process for the preparation thereof
JP3983979B2 (ja) 3−(ヒドロキシメチル)クロメン−4−オン類およびその製造方法